Mogamulizumab, a humanized anti-CCR4 monoclonal antibody, received FDA and EMA approval in 2018 for the treatment of adults with relapsed or refractory MF/SS following at least one systemic therapy. This evidence concerns the gene CCR4 and synovial sarcoma.